Bacterial Lipopolysaccharide, Lipopolysaccharide-Binding Protein, and Other Inflammatory Markers in Obesity and After Bariatric Surgery

2016 ◽  
Vol 14 (6) ◽  
pp. 279-288 ◽  
Author(s):  
Kathryn Tuomi ◽  
John V. Logomarsino
Keyword(s):  
Bariatric Surgery ◽  
Inflammatory Markers ◽  
Binding Protein ◽  
Bacterial Lipopolysaccharide ◽  
Lipopolysaccharide Binding Protein ◽  
Lipopolysaccharide Binding

scholarly journals Rosuvastatin Decreases Intestinal Fatty Acid Binding Protein (I-FABP), but does not Alter Zonulin or Lipopolysaccharide Binding Protein (LBP) Levels, in HIV-Infected Subjects on Antiretroviral Therapy

2016 ◽  
Vol 1 (1) ◽  
pp. 118 ◽  
Author(s):  
Nicholas Funderburg ◽  
Morgan Boucher ◽  
Abdus Sattar ◽  
Manjusha Kulkarni ◽  
Danielle Labbato ◽  
...  
Keyword(s):  
Fatty Acid ◽  
Immune Activation ◽  
Inflammatory Markers ◽  
Fatty Acid Binding Protein ◽  
Binding Protein ◽  
Lipopolysaccharide Binding Protein ◽  
Fatty Acid Binding ◽  
Barrier Integrity ◽  
Acid Binding Protein ◽  
Lipopolysaccharide Binding

Introduction: Altered gastrointestinal (GI) barrier integrity and subsequent microbial translocation may contribute to immune activation in HIV infection. We have reported that rosuvastatin improved several markers of immune activation in HIV+ participants, but the effect of statin treatment on markers of GI barrier dysfunction is unknown.Methods: SATURN-HIV is a randomized, double-blind, placebo-controlled trial assessing the effect of rosuvastatin (10mg/daily) on markers of cardiovascular disease, inflammation, and immune activation in ART-treated patients. Gut-barrier integrity was assessed by the surrogate markers intestinal fatty acid binding protein (I-FABP), a marker of enterocyte death, and zonulin-1, a marker of gut epithelial cell function. Levels of lipopolysaccharide binding protein (LBP) were measured as a marker of microbial translocation.Results: Rosuvastatin significantly reduced levels of I-FABP during the treatment period compared to the placebo. There was no effect of rosuvastatin treatment on levels of zonulin or LBP. Baseline levels of LBP were directly related to several markers of immune activation in samples from all participants, including soluble CD163, IP-10, VCAM-1, TNFR-II, and the proportion of CD4+ and CD8+ T cells expressing CD38 and HLA-DR. Many of these relationships, however, were not seen in the statin arm alone at baseline or over time, as inflammatory markers often decreased and LBP levels were unchanged.Conclusions: Forty-eight weeks of rosuvastatin treatment reduced levels of I-FABP, but did not affect levels of zonulin or LBP. The reduction in levels of inflammatory markers that we have reported with rosuvastatin treatment is likely mediated through other mechanisms not related to gut integrity or microbial translocation.SATURN-HIV is registered on clinicaltrials.gov; Identifier: NCT01218802

Lipopolysaccharide and lipopolysaccharide-binding protein levels and their relationship to early metabolic improvement after bariatric surgery

2015 ◽  
Vol 11 (4) ◽  
pp. 933-939 ◽  
Author(s):  
Mercedes Clemente-Postigo ◽  
Maria del Mar Roca-Rodriguez ◽  
Antonio Camargo ◽  
Luis Ocaña-Wilhelmi ◽  
Fernando Cardona ◽  
...  
Keyword(s):  
Bariatric Surgery ◽  
Binding Protein ◽  
Lipopolysaccharide Binding Protein ◽  
Protein Levels ◽  
Lipopolysaccharide Binding

Serum Lipopolysaccharide-Binding Protein is Associated with Chronic Inflammation and Metabolic Syndrome in Hemodialysis Patients

2018 ◽  
Vol 47 (1-3) ◽  
pp. 28-36 ◽  
Author(s):  
Paik Seong Lim ◽  
Yu-Kang Chang ◽  
Tsai-Kun Wu
Keyword(s):  
Metabolic Syndrome ◽  
Chronic Inflammation ◽  
Inflammatory Markers ◽  
Binding Protein ◽  
Fasting Blood Glucose ◽  
High Sensitivity ◽  
Acute Phase Reactant ◽  
Lipopolysaccharide Binding Protein ◽  
Markers Of Inflammation ◽  
Lipopolysaccharide Binding

Background: In hemodialysis (HD) patients, impaired gut barrier and alteration in microbiota in the gut is thought to increase the risk of bacterial translocation and chronic inflammation. Lipopolysaccharide-binding protein (LBP) is an acute-phase reactant that mediates immune responses triggered by microbial products. Our aim is to investigate the relationship between circulating levels of LBP, and various metabolic and inflammatory markers in HD patients. Besides, we also aim to determine its relationship among ­patients with different body mass index. Patients and Methods: A total of 123 HD patients were stratified into three ­tertiles, according to serum LBP level. The LBP and inflammatory markers were determined using immunoassay methods. A bioimpedance spectroscopy device was used for body composition measurement. Results: The serum levels of the two proinflammatory markers, high-sensitivity C-reactive protein (hsCRP) and interleukin (IL)-6, were significantly higher in patients in the upper tertile when compared with the rest of the tertiles. In HD patients, a significant positive correlation was found between serum LBP levels and CRP, IL-6, soluble CD14 (sCD14), and fasting blood glucose levels. Patients with metabolic syndrome and pre-existing cardiovascular disease had higher LBP levels than those without metabolic syndrome. Besides, obese patients were also associated with higher serum LBP levels. Multivariate regression analyses showed that IL-6 level was the strongest correlate of LBP level, followed by hsCRP level and sCD14. Conclusions: Our study suggested that elevated plasma LBP was associated with metabolic syndrome and obesity. In addition, increased LBP level was correlated positively to markers of inflammation, and sCD14 levels.

Bariatric surgery decreased the serum level of an endotoxin-associated marker: lipopolysaccharide-binding protein

2014 ◽  
Vol 10 (6) ◽  
pp. 1182-1187 ◽  
Author(s):  
Po-Jen Yang ◽  
Wei-Jei Lee ◽  
Ping-Huei Tseng ◽  
Po-Huang Lee ◽  
Ming-Tsan Lin ◽  
...  
Keyword(s):  
Bariatric Surgery ◽  
Serum Level ◽  
Binding Protein ◽  
Lipopolysaccharide Binding Protein ◽  
Lipopolysaccharide Binding

scholarly journals Higher Lipopolysaccharide Binding Protein and Chemerin Concentrations Were Associated with Metabolic Syndrome Features in Pediatric Subjects with Abdominal Obesity during a Lifestyle Intervention

Nutrients ◽  
2021 ◽  
Vol 13 (2) ◽  
pp. 289
Author(s):  
Amelia Marti ◽  
Isabel Martínez ◽  
Ana Ojeda-Rodríguez ◽  
María Cristina Azcona-Sanjulian
Keyword(s):  
Metabolic Syndrome ◽  
Children And Adolescents ◽  
Lifestyle Intervention ◽  
Abdominal Obesity ◽  
Plasma Levels ◽  
Intervention Program ◽  
Binding Protein ◽  
Controlled Trial ◽  
Lipopolysaccharide Binding Protein ◽  
Lipopolysaccharide Binding

Background: Elevated circulating plasma levels of both lipopolysaccharide-binding protein (LBP) and chemerin are reported in patients with obesity, but few studies are available on lifestyle intervention programs. We investigated the association of both LBP and chemerin plasma levels with metabolic syndrome (MetS) outcomes in a lifestyle intervention in children and adolescents with abdominal obesity Methods: Twenty-nine patients enrolled in a randomized controlled trial were selected. The lifestyle intervention with a 2-month intensive phase and a subsequent 10-month follow-up consisted of a moderate calorie-restricted diet, recommendations to increase physical activity levels, and nutritional education. Results: Weight loss was accompanied by a significant reduction in MetS prevalence (−43%; p = 0.009). Chemerin (p = 0.029) and LBP (p = 0.033) plasma levels were significantly reduced at 2 months and 12 months, respectively. At the end of intervention, MetS components were associated with both LBP (p = 0.017) and chemerin (p < 0.001) plasma levels. Conclusions: We describe for the first time a reduction in both LBP and chemerin plasma levels and its association with MetS risk factors after a lifestyle intervention program in children and adolescents with abdominal obesity. Therefore, LBP and chemerin plasma levels could be used as biomarkers for the progression of cardiovascular risk in pediatric populations.

scholarly journals Microbiome-Metabolomics Reveals Prebiotic Benefits of Fucoidan Supplementation in Mice

2021 ◽  
Vol 9 (5) ◽  
pp. 505
Author(s):  
Jingyi Yuan ◽  
Song Qin ◽  
Wenjun Li ◽  
Yubing Zhang ◽  
Yuting Wang ◽  
...  
Keyword(s):  
Lipid Metabolism ◽  
Triglyceride Level ◽  
Lactobacillus Reuteri ◽  
Binding Protein ◽  
Serum Triglyceride ◽  
Serum Triglyceride Level ◽  
Lipopolysaccharide Binding Protein ◽  
Lactobacillus Gasseri ◽  
Lactobacillus Animalis ◽  
Lipopolysaccharide Binding

Fucoidan is a kind of polysaccharide with antitumor and antioxidant properties, which is mainly isolated from brown algae. Although there are many reports about the prebiotic effects of polysaccharides on hosts, there are few reports about the effects of fucoidan on blood biochemical indexes, intestinal microbiome, and metabolic function on healthy hosts. We applied 16S rRNA gene amplicon sequencing and LC-MS/MS metabolomics to evaluate the changes in the gut microbiome and metabolite profiles of fucoidan treatment in mice over 10 weeks. Fucoidan treatment modulated lipid metabolism, including significantly decreasing serum triglyceride level in healthy mice. Fucoidan also significantly inhibited serum lipopolysaccharide-binding protein (LBP) concentration, a biomarker of endotoxemia. Correlation analysis further showed that Lactobacillus animalis populations that were enriched by fucoidan demonstrated significantly negative correlations with serum triglyceride level. The abundance of Lactobacillus gasseri and Lactobacillus reuteri, increased by fucoidan supplementation, demonstrated significantly negative correlation with lipopolysaccharide-binding protein levels. Lactobacillus gasseri also demonstrated significantly positive correlations with three tryptophan-related metabolites, including indoleacrylic acid, 3-indoleacrylic acid, and 5-hydroxytryptamine, which were all increased by fucoidan administration. Combined with the previous evidence, the results indicate that fucoidan exerts prebiotic effects, such as lipid metabolism suppression and metabolic endotoxemia suppression, by modulating the abundance of gut microbiota, such as Lactobacillus animalis, Lactobacillus gasseri, and Lactobacillus reuteri, as well as microbiota-dependent metabolites, such as tryptophan-related metabolites.

Gene variants of the bactericidal/permeability increasing protein and lipopolysaccharide binding protein in sepsis patients

2001 ◽  
Vol 29 (3) ◽  
pp. 557-561 ◽  
Author(s):  
Jaroslav A. Hubacek ◽  
Frank Stüber ◽  
Dieter Fröhlich ◽  
Malte Book ◽  
Silke Wetegrove ◽  
...  
Keyword(s):  
Binding Protein ◽  
Gene Variants ◽  
Lipopolysaccharide Binding Protein ◽  
Lipopolysaccharide Binding
Sign in / Sign up

Export Citation Format

Share Document